Evidence map›Paper›PMID 37937555›Full record

ReviewRecent patents on nanotechnology2025

Diabetology and Nanotechnology: A Compelling Combination.

Ritu Karwasra, Shivkant Sharma, Isha Sharma, Nida Shahid, Tarana Umar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent patents on nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  2. Review
  3. Review
  4. Diabetic neuropathy: cutting-edge research and future directions.Signal transduction and targeted therapy · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ritu KarwasraCentral Council for Research in Unani Medicine (CCRUM), Ministry of AYUSH, Government of India, New Delhi, 110058, India.
Shivkant SharmaDepartment of Pharmaceutical Sciences, Gurugram University, Gurugram, 122018, India.
Isha SharmaDepartment of Pharmaceutical Sciences, Gurugram University, Gurugram, 122018, India.
Nida ShahidDepartment of Chemistry, Jamia Milia Islamia University, Jamia Nagar, Okhla, New Delhi, 110025, India.
Tarana UmarCentral Council for Research in Unani Medicine (CCRUM), Ministry of AYUSH, Government of India, New Delhi, 110058, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The convergence of diabetology and nanotechnology has emerged as a promising synergy with the potential to revolutionize the management and treatment of diabetes mellitus. Diabetes, a complex metabolic disorder affecting millions worldwide, necessitates innovative approaches to enhance monitoring, diagnosis, and therapeutic interventions. Nanotechnology, a burgeoning field that manipulates materials at the nanoscale, offers unprecedented opportunities to address the challenges posed by diabetes. This abstract explores the multifaceted interface between diabetology and nanotechnology, highlighting key areas of integration. Nanotechnology has paved the way for the development of advanced glucose monitoring systems with enhanced accuracy, sensitivity, and patient convenience. Miniaturized biosensors and implantable devices equipped with nanoscale materials enable continuous and real-time glucose monitoring, empowering individuals with diabetes to make timely and informed decisions about their dietary and insulin management. Furthermore, nanotechnology has facilitated breakthroughs in targeted drug delivery, addressing the limitations of conventional therapies in diabetes treatment. Nano-sized drug carriers can improve bioavailability, enable controlled release, and enhance the selectivity of therapeutic agents, minimizing side effects and optimizing treatment outcomes. Moreover, nanoengineered materials have opened avenues for tissue engineering and regenerative medicine, offering the potential to restore damaged pancreatic islets and insulin-producing cells. The amalgamation of diabetology and nanotechnology also holds promise for early disease detection and prevention. Nanoscale diagnostic tools, such as biomarker-based nanoprobes and lab-onchip devices, offer rapid and accurate detection of diabetes-related biomolecules, enabling timely interventions and reducing the risk of complications. However, this compelling combination also presents challenges that warrant careful consideration. Safety, biocompatibility, regulatory approval, and ethical implications are crucial factors that demand meticulous evaluation during the translation of nanotechnology-based solutions into clinical practice. In conclusion, the integration of diabetology and nanotechnology represents a transformative paradigm that has the potential to reshape the landscape of diabetes management. By harnessing the unique properties of nanoscale materials, researchers and clinicians are poised to usher in an era of personalized and precise diagnostics, therapeutics, and preventive strategies for diabetes mellitus. As advancements in nanotechnology continue to unfold, the journey towards realizing the full potential of this compelling combination remains an exciting frontier in medical science. This review has thoroughly and critically studied the usage of nanomedicine in the diagnosis, monitoring, and management of diabetes and its effects, providing a clear picture of their potential clinical application in the future. This evaluation covers additional numerous clinical trials research and patents that are currently in way in this subject. Thus in the light of this we intended to provide a broad picture of the state of technological development in the area of diabetes management through nanotechnology.

Indexed as

Diabetes MellitusNanotechnologyAnimalsBiosensing TechniquesDrug Delivery SystemsHumansHypoglycemic AgentsInsulinHypoglycemic AgentsInsulinanti-diabetic drug deliverydiabetes mellitusdiagnosisnanoparticlesnanoscale diagnostic tools.Nanotechnology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.